Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.66 |
| ▸ | TUBB | P07437 | 2/20 | 0.66 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.66 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.66 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.66 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.66 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.66 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.66 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.66 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.66 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.66 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.66 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.66 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Wr-190433 SCHEMBL30880222 | 1.00 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Wr-190433 SCHEMBL29870441 | 1.00 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Wr-190433 SCHEMBL6180067 | 1.00 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15882450 | 0.94 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15882451 | 0.94 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11473136 | 0.91 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11473133 | 0.91 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28713225 | 0.88 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1604279 | 0.88 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9700985 | 0.86 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235348-A1 | MACHINE-LEARNED MODELS FOR PROCESSING STRUCTURAL REPRESENTATIONS OF THERAPEUTIC MATERIALS | GOOGLE LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2005121129-A1 | NOVEL PROPENONE DERIVATIVES CONTAINING AROMATIC RINGS, A MAUFACTURING PROCESS THEREOF AND A COMPOSITION CONTAINING THE SAME USING AS AN ANTIINFLAMMATORY AGENT | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2005-12-22 | — | — | WO | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6878729-B2 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| EP-0187711-B1 | OCTAHYDROINDOLIZINE COMPOUNDS USEFUL AS ANALGESICS | McNeilab, Inc. (US) | 1990-08-29 | — | — | EP | disclosed |
| EP-0187711-A2 | Octahydroindolizine compounds useful as analgesics | McNeilab, Inc. (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4582836-A | Octahydroindolizine compounds useful as analgesics | MCNEILAB, INC. (US) | 1986-04-15 | — | — | US | disclosed |
| US-4284829-A | Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives | PFIZER INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4283569-A | Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives | PFIZER INC. (US) | 1981-08-11 | — | — | US | disclosed |
| US-4014889-A | Process for preparing ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
| US-3991197-A | ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1976-11-09 | — | — | US | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | TUBB4A 1158/4885TUBB 1335/4885TUBA3C 2006/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | TUBB4A 1190/4885TUBB 1393/4885TUBA3C 2118/4885 |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, FLT4 | TUBB4A 136/4885TUBB 139/4885TUBA3C 332/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | TUBB4A 998/4885TUBB 947/4885TUBA3C 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.